We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+20.67%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.1B
AUM Growth
+$302M
(+17%)
Cap. Flow
+$69.4M
Cap. Flow
% of AUM
3.31%
Top 10 Holdings %
Top 10 Hldgs %
39.8%
Holding
89
New
37
Increased
12
Reduced
15
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$75.2M |
| 2 |
AET
Aetna Inc
AET
|
+$68.6M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$55.8M |
| 4 |
Brookdale Senior Living
BKD
|
+$51.1M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$50.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$120M |
| 2 |
Bausch Health
BHC
|
+$93M |
| 3 |
Pfizer
PFE
|
+$76.9M |
| 4 |
Keysight
KEYS
|
+$69M |
| 5 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$60.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.75% |
| 2 | Financials | 3.56% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $104M | 4.96% |
4,000,000
-1,600,000
| -29% | -$29.3M |
|
|
MNK
2
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $101M | 4.83% |
800,000
-525,000
| -40% | -$60M |
|
|
3
CALL
Gilead Sciences
GILD
$163B
| $98.1M | 4.68% |
+1,000,000
| New | +$102M |
|
4
Labcorp
LH
$25.9B
| $85.1M | 4.06% |
785,700
+145,500
| +23% | +$15M |
|
|
5
Biogen
BIIB
$30.7B
| $80.5M | 3.84% |
+190,700
| New | +$75.2M |
|
6
CALL
Agilent Technologies
A
$39.2B
| $75.8M | 3.62% |
1,825,000
+25,000
| +1% | +$1.01M |
|
|
AET
7
DELISTED
Aetna Inc
AET
| $74.6M | 3.56% |
+700,000
| New | +$68.6M |
|
|
8
Brookdale Senior Living
BKD
$3.49B
| $73.6M | 3.51% |
1,950,000
+1,396,500
| +252% | +$51.1M |
|
|
9
Teva Pharmaceuticals
TEVA
$41.2B
| $71.6M | 3.42% |
1,150,000
+866,000
| +305% | +$50.4M |
|
|
10
CALL
Pfizer
PFE
$142B
| $69.6M | 3.32% |
2,108,000
+1,581,000
| +300% | +$50.3M |
|
11
Viatris
VTRS
$20.7B
| $68M | 3.25% |
1,146,400
+447,600
| +64% | +$25.5M |
|
|
12
Jazz Pharmaceuticals
JAZZ
$16.2B
| $56.2M | 2.68% |
+325,000
| New | +$55.8M |
|
|
TSRO
13
DELISTED
TESARO, Inc.
TSRO
| $53.1M | 2.53% |
925,000
-125,000
| -12% | -$5.89M |
|
|
MDVN
14
DELISTED
MEDIVATION, INC.
MDVN
| $48.4M | 2.31% |
750,000
-400,000
| -35% | -$22.9M |
|
|
15
CALL
Viatris
VTRS
$20.7B
| $47.5M | 2.27% |
+800,000
| New | +$45.6M |
|
|
KND
16
DELISTED
Kindred Healthcare
KND
| $46.6M | 2.23% |
+1,960,800
| New | +$39.8M |
|
|
RAD
17
DELISTED
Rite Aid Corporation
RAD
| $45.7M | 2.18% |
+263,145
| New | +$41M |
|
18
CALL
Danaher
DHR
$138B
| $44.1M | 2.11% |
773,673
+178,540
| +30% | +$10.2M |
|
|
19
CALL
Teva Pharmaceuticals
TEVA
$41.2B
| $43.6M | 2.08% |
+700,000
| New | +$40.7M |
|
20
Boston Scientific
BSX
$68.4B
| $42.4M | 2.02% |
2,386,700
-1,074,500
| -31% | -$17M |
|
21
Merck
MRK
$321B
| $41.3M | 1.97% |
+753,512
| New | +$42.7M |
|
|
ALR
22
DELISTED
Alere Inc
ALR
| $39.1M | 1.87% |
+799,900
| New | +$35.1M |
|
|
WBMD
23
DELISTED
WebMD Health Corp.
WBMD
| $37.5M | 1.79% |
855,555
-369,445
| -30% | -$15.3M |
|
24
Illumina
ILMN
$31B
| $36M | 1.72% |
199,535
-160,265
| -45% | -$30.2M |
|
25
Edwards Lifesciences
EW
$50B
| $35.6M | 1.7% |
+1,500,000
| New | +$33.7M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2015 Portfolio in Review
As of Q1 2015, HealthCor Management held 89 positions worth $2.1B, up 17% from $1.79B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
HealthCor Management deployed $69.4M of net new capital in Q1 2015, opening 37 new positions and adding to 12 existing holdings. Its largest new stake was Biogen: 190,700 shares worth $80.5M.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 72% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Gilead Sciences, an estimated $120M trimmed.
- HealthCor Management's largest Q1 2015 buy was Biogen: 190,700 shares worth $80.5M.
- HealthCor Management added most to Brookdale Senior Living in Q1 2015, an estimated $51.1M increase.
- HealthCor Management's biggest Q1 2015 reduction was Gilead Sciences, cutting an estimated $120M.
- HealthCor Management fully exited Bausch Health in Q1 2015, selling an estimated $93M.
- HealthCor Management's ten largest holdings make up 40% of its $2.1B portfolio in Q1 2015.
- HealthCor Management opened 37 new positions and closed 24 in Q1 2015.
- HealthCor Management's portfolio value rose 17% quarter-over-quarter to $2.1B.
Based on HealthCor Management's 13F filing for Q1 2015, filed 15 May 2015.